Paraoxonase 1 polymorphisms L55M and Q192R were not risk factors for Parkinson's disease: A HuGE review and meta-analysis

Gene

Volumn 501, Issue 2, 2012, Pages 188-192

  Liu, Ying Li ^a   Yang, Jie ^a   Zheng, Jie ^b   Liu, Dian Wu ^a   Liu, Tian ^a   Wang, Jian Min ^a   Wang, Chao Nan ^a   Wang, Ming Wei ^a   Tian, Qing Bao ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI GENERAL HOSPITAL   (China)

Author keywords

HuGE review; Meta analysis; Parkinson's disease; Polymorphisms; PON1

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1;

ANALYTIC METHOD; ARTICLE; EGGER TEST; ENZYME POLYMORPHISM; FUNNEL PLOT; GENETIC ASSOCIATION; GENETIC MODEL; GENOTYPE; PARKINSON DISEASE; PRIORITY JOURNAL; PUBLISHING; RISK ASSESSMENT;

ARYLDIALKYLPHOSPHATASE; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MODELS, GENETIC; PARKINSON DISEASE; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 84860761109     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.03.067     Document Type: Article

References (38)

1. Akhmedova S., Anisimov S., Yakimovsky A., Schwartz E. Gln->Arg 191 polymorphism of paraoxonase and Parkinson's disease. Hum. Hered. 1999, 49:178-180.
2. Akhmedova S.N., Yakimovsky A.K., Schwartz E.I. Paraoxonase 1 Met-Leu 54 polymorphism is associated with Parkinson's disease. J. Neurol. Sci. 2001, 184:179-182.
3. Carmine A., Buervenich S., Sydow O., Anvret M., Olson L. Further evidence for an association of the paraoxonase 1 (PON1) Met-54 allele with Parkinson's disease. Mov. Disord. 2002, 17:764-766.
4. Chapuis J., Boscher M., Bensemain F., Cottel D., Amouyel P., Lambert J.C. Association study of the paraoxonase 1 gene with the risk of developing Alzheimer's disease. Neurobiol. Aging 2009, 30:152-156.
5. Clarimon J., Eerola J., Hellstrom O., Tienari P.J., Singleton A. Paraoxonase 1 (PON1) gene polymorphisms and Parkinson's disease in a Finnish population. Neurosci. Lett. 2004, 367:168-170.
6. Dahabreh I.J., Kitsios G.D., Kent D.M., Trikalinos T.A. Paraoxonase 1 polymorphisms and ischemic stroke risk: a systematic review and meta-analysis. Genet. Med. 2010, 12:606-615.
7. Davies H.G., Richter R.J., Keifer M., Broomfield C.A., Sowalla J., Furlong C.E. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet. 1996, 14:334-336.
8. Dick F.D., et al. Gene-environment interactions in parkinsonism and Parkinson's disease: the Geoparkinson study. Occup. Environ. Med. 2007, 64:673-680.
9. Ergun M.A., et al. PON1 55 and 192 gene polymorphisms in type 2 diabetes mellitus patients in a Turkish population. Biochem. Genet. 2011, 49:1-8.
10. Gonzalez-Herrera L., et al. Paraoxonase 1 polymorphisms and haplotypes and the risk for having offspring affected with spina bifida in Southeast Mexico. Birth Defects Res. A Clin. Mol. Teratol. 2010, 88:987-994.
11. Hashemi M., et al. The L55M polymorphism of paraoxonase-1 is a risk factor for rheumatoid arthritis. Genet. Mol. Res. 2010, 9:1735-1741.
12. Hillier L.W., et al. The DNA sequence of human chromosome 7. Nature 2003, 424:157-164.
13. Kelada S.N., et al. Paraoxonase 1 promoter and coding region polymorphisms in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2003, 74:546-547.
14. Kondo I., Yamamoto M. Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease. Brain Res. 1998, 806:271-273.
15. Lagos K.G., et al. Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids 2009, 44:9-16.
16. Lau J., Ioannidis J.P., Schmid C.H. Quantitative synthesis in systematic reviews. Ann. Intern. Med. 1997, 127:820-826.
17. Li W.F., et al. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 2000, 10:767-779.
18. Li W.F., Furlong C.E., Costa L.G. Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol. Lett. 1995, 76:219-226.
19. MacKness B., et al. Paraoxonase activity in two healthy populations with differing rates of coronary heart disease. Eur. J. Clin. Invest. 2000, 30:4-10.
20. Manthripragada A.D., Costello S., Cockburn M.G., Bronstein J.M., Ritz B. Paraoxonase 1, agricultural organophosphate exposure, and Parkinson disease. Epidemiology 2010, 21:87-94.
21. Mochizuki H., et al. Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 1998, 213:149-157.
22. Momose Y., et al. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann. Neurol. 2002, 51:133-136.
23. Paragh G., et al. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 1998, 80:166-170.
24. Scacchi R., Corbo R.M., Rickards O., De Stefano G.F. New data on the world distribution of paraoxonase (PON1 Gln 192->Arg) gene frequencies. Hum. Biol. 2003, 75:365-373.
25. Senti M., et al. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J. Clin. Endocrinol. Metab. 2003, 88:5422-5426.
26. Shih D.M., et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998, 394:284-287.
27. Soran N., Altindag O., Cakir H., Celik H., Demirkol A., Aksoy N. Assessment of paraoxonase activities in patients with knee osteoarthritis. Redox Rep. 2008, 13:194-198.
28. Tan E.K., Khajavi M., Thornby J.I., Nagamitsu S., Jankovic J., Ashizawa T. Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 2000, 55:533-538.
29. Tavori H., et al. Human carotid atherosclerotic plaque increases oxidative state of macrophages and low-density lipoproteins, whereas paraoxonase 1 (PON1) decreases such atherogenic effects. Free Radic. Biol. Med. 2009, 46:607-615.
30. Taylor M.C., Le Couteur D.G., Mellick G.D., Board P.G. Paraoxonase polymorphisms, pesticide exposure and Parkinson's disease in a Caucasian population. J. Neural Transm. 2000, 107:979-983.
31. Toda T., et al. Toward identification of susceptibility genes for sporadic Parkinson's disease. J. Neurol. 2003, 250(Suppl. 3):III40-III43.
32. Wang J., Liu Z. No association between paraoxonase 1 (PON1) gene polymorphisms and susceptibility to Parkinson's disease in a Chinese population. Mov. Disord. 2000, 15:1265-1267.
33. Wingo T.S., Rosen A., Cutler D.J., Lah J.J., Levey A.I. Paraoxonase-1 polymorphisms in Alzheimer's disease, Parkinson's disease, and AD-PD spectrum diseases. Neurobiol. Aging 2012, 33:204. e13-5.
34. Xie S., Li J., Chen Y., Wang C., Zhang H., Mo D. Sequence identification, chromosomal mapping and tissue specific expression of the porcine paraoxonase 1 (PON1) gene. Mol. Biol. Rep. 2010, 37:1347-1353.
35. Yildiz A., et al. Paraoxonase and arylesterase activities in untreated dipper and non-dipper hypertensive patients. Clin. Biochem. 2008, 41:779-784.
36. Zintzaras E., Hadjigeorgiou G.M. Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: a meta-analysis. J. Hum. Genet. 2004, 49:474-481.
37. Zintzaras E., Ioannidis J.P. Heterogeneity testing in meta-analysis of genome searches. Genet. Epidemiol. 2005, 28:123-137.
38. Zintzaras E., Lau J. Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J. Clin. Epidemiol. 2008, 61:634-645.